Halozyme Therapeutics hits fresh record after increased $1.3 bln convertible bond sale

Halozyme Therapeutics

18/09/2026 15:41

** Shares of Halozyme Therapeutics HALO.O up 0.8% at $110.55 and touch fresh record high on Fri after it secures more capital than planned
** HALO rises as much as 1.9% to $111.80, surpassing previous all-time intraday high of $111.15 achieved on Sept 3
** San Diego, California-based drug delivery firm late Thurs announced pricing private offering of $1.3 bln 1.5% convertible bonds (CBs) due Oct 1, 2033
** Conversion price of $139.84 is 27.5% premium above stock's last sale of $109.68 on Thurs
** HALO finished up 1% on Thurs after co launched $1.05 bln offering to repurchase its outstanding 0.25% CBs due 2027 and 1% CBs due 2028; remainder earmarked for working capital, capex, potential acquisitions, among other uses
** Co expects to use approx $162.6 mln of proceeds to fund capped call transactions to mitigate potential dilution; cap price of $209.39 is 90% premium over stock's last close
** HALO now up 64% YTD
** Avg rating of 10 analysts is "buy"; median PT of $105 up from $90 on June 18, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))